| Literature DB >> 31694283 |
Simayijiang Aimaiti1, Yohei Saito1, Shuichi Fukuyoshi1, Masuo Goto2, Katsunori Miyake3, David J Newman4, Barry R O'Keefe5,6, Kuo-Hsiung Lee2,7, Kyoko Nakagawa-Goto1,2.
Abstract
Seven new butanolides, peltanolides A-G (1-7), and two lignan glucosides, peltasides A (8) and B (9), along with eleven known compounds, 10-20, were isolated from a crude CH3OH/CH2Cl2 (1:1) extract of the fruit of Hernandia nymphaeifolia (Hernandiaceae). The structures of 1-9 were characterized by extensive 1D and 2D NMR spectroscopic and HRMS analysis. The absolute configurations of newly isolated compounds 1-9 were determined from data obtained by optical rotation and electronic circular dichroism (ECD) exciton chirality methods. Butanolides and lignan glucosides have not been isolated previously from this genus. Several isolated compounds were evaluated for antiproliferative activity against human tumor cell lines. Lignans 15 and 16 were slightly active against chemosensitive tumor cell lines A549 and MCF-7, respectively. Furthermore, both compounds displayed significant activity (IC50 = 5 µM) against a P-glycoprotein overexpressing multidrug-resistant tumor cell line (KB-VIN) but were less active against its parent chemosensitive cell line (KB).Entities:
Keywords: Hernandia nymphaeifolia; antiproliferative activity; butanolides; lignan glycosides
Mesh:
Substances:
Year: 2019 PMID: 31694283 PMCID: PMC6864620 DOI: 10.3390/molecules24214005
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Isolated compounds (1−20) from H. nymphaeifolia.
1H NMR Spectroscopic data of compounds 1−7.
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
|---|---|---|---|---|---|---|---|
| Position | |||||||
| 1 | 2.15 s | ||||||
| 3 | 5.26 brs | 5.26 brs | 5.26 brd (5.6) | 5.11 m | 5.10 brd (7.3) | 4.82 brs | 4.89 d (4.2) |
| 5a | 4.72 dd (2.8, 1.4) | 4.72 dd (2.8, 1.4) | 4.72 dd (2.8, 1.4) | 4.67 dd (2.8, 1.4) | 4.66 dd (2.8, 1.4) | 1.62 s | 7.07 t (8.0) |
| 5b | 4.96 dd (2.8, 1.4) | 4.96 dd (2.8, 1.4) | 4.96 dd (2.8, 1.4) | 4.89 dd (2.8, 1.4) | 4.89 dd (2.8, 1.4) | ||
| 6 | 7.09 td (7.8, 2.2) | 7.09 td (7.8, 2.2) | 7.10 td (7.8, 2.2) | 6.69 td (7.8, 2.2) | 6.67 td (7.8, 2.2) | 7.04 td (7.8, 2.2) | 2.34 td (14.8, 8.0) |
| 7 | 2.48 m | 2.48 m | 2.48 m, 2.43 m | 2.78 m | 2.76 m | 2.38 m | 1.50 m |
| 8 | 1.52 m | 1.52 m | 1.53 m | 1.46 m | 1.45 m | 1.52 m | 1.25 mp |
| 9–18 | 1.26 mc | 1.26 me | 1.25 mg | 1.25 mh | 1.25 mj | 1.25 mm | 1.25 mp |
| 19 | 2.00 m | 1.26 me | 1.25 mg | 1.25 mh | 1.25 mj | 2.01 mn | 2.00 mq |
| 20 | 5.36 md | 1.26 me | 1.25 mg | 1.25 mh | 1.25 mj | 5.34 t (4.8)o | 5.34 t (4.8)r |
| 21 | 5.36 md | 1.26 me | 1.25 mg | 2.02 m | 1.25 mj | 5.34 t (4.8)o | 5.34 t (4.8)r |
| 22 | 2.02 m | 1.26 me | 1.25 mg | 5.35 mi | 1.25 mj | 2.01 mn | 2.00 mq |
| 23 | 1.26 mc | 2.00 m | 1.25 mg | 5.35 mi | 2.01 mk | 1.25 mm | 1.25 mp |
| 24 | 1.32 m | 5.36 mf | 1.25 mg | 2.02 | 5.33 ml | 1.31 | 1.25 mp |
| 25 | 0.89 t (6.9) | 5.36 mf | 0.89 br t (7.3) | 1.25 mh | 5.33 ml | 0.89 t (6.0) | 1.31 m |
| 26 | 2.02 m | 1.33 m | 2.01 mk | 0.89 t (6.0) | |||
| 27 | 1.26 me | 0.88 t (6.9) | 1.25 mj | ||||
| 28 | 1.32 m | 1.32 m | |||||
| 29 | 0.89 t (7.3) | 0.87 t (6.9) | |||||
| 2-OH | 2.26 m | ||||||
| 3-OH | 4.00 brs | ||||||
| OCH3 | 3.72 s |
600 MHz, 400 MHz, Overlapping signals.
13C NMR Spectroscopic data in CDCl3 of compounds 1−7.
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
|---|---|---|---|---|---|---|---|
| Position |
|
|
|
|
|
|
|
| 1 | 166.5 | 166.5 | 166.3 | 163.1 | 166.4 | 24.8 | |
| 2 | 127.3 | 127.3 | 127.2 | 127.4 | 127.3 | 125.2 | 206.3 |
| 3 | 66.5 | 66.5 | 66.6 | 68.9 | 68.9 | 70.9 | 73.4 |
| 4 | 157.6 | 157.6 | 157.5 | 160.1 | 160.2 | 100.1 | 129.8 |
| 5 | 91.4 | 91.4 | 91.5 | 90.3 | 90.4 | 26.8 | 149.0 |
| 6 | 150.3 | 150.3 | 150.3 | 151.4 | 151.4 | 151.9 | 28.7 |
| 7 | 29.8 | 29.8 | 29.8 | 29.8 | 29.8 | 30.1 | 29.3 |
| 8 | 28.4 | 28.4 | 28.4–29.6d | 28.4 | 28.4 | 29.5–29.9g | 29.4–30.0h |
| 9–18 | 29.4–30.0 | 29.4–30.0c | 28.4–29.6d | 29.4–30.0e | 29.4–30.0f | 29.5–29.9g | 29.4–30.0h |
| 19 | 27.0 | 29.4–30.0c | 28.4–29.6d | 29.4–30.0e | 29.4–30.0f | 27.0 | 27.2 |
| 20 | 129.8 | 29.4–30.0c | 28.4–29.6d | 29.4–30.0e | 29.4–30.0f | 129.8 | 129.8 |
| 21 | 129.9 | 29.4–30.0c | 28.4–29.6d | 27.0 | 29.4–30.0f | 129.9 | 129.9 |
| 22 | 27.2 | 29.4–30.0c | 28.4–29.6d | 129.8 | 29.4–30.0f | 27.7 | 27.2 |
| 23 | 32.0 | 27.0 | 32.0 | 129.9 | 27.0 | 32.1 | 29.8 |
| 24 | 22.4 | 129.8 | 22.8 | 27.2 | 129.8 | 22.5 | 31.9 |
| 25 | 14.0 | 129.9 | 14.1 | 32.0 | 129.9 | 14.1 | 22.7 |
| 26 | 27.2 | 22.3 | 27.2 | 14.1 | |||
| 27 | 32.0 | 14.0 | 32.0 | ||||
| 28 | 22.4 | 22.4 | |||||
| 29 | 14.0 | 14.0 | |||||
| COO | 166.5 | ||||||
| OCH3 | 52.0 |
150 MHz, 100 MHz, Overlapping signals.
Figure 2Selected HMBC correlations (arrows in red), COSY connectivities (bold lines) for compounds 1−7.
Figure 3Key NOESY (red dashed lines) correlations for compounds 1–7.
Figure 4Experimental and calculated ECD spectra of compounds 6 and 7.
Figure 5EIMS fragmentation of 7.
Figure 6Selected HMBC correlations (arrows in red), COSY connectivities (bold lines) for 8 and 9.
Figure 7Key NOESY correlations (red lines) and Key ROESY correlations (blue lines) for 8 and 9.
Figure 8Experimental ECD spectra of compounds 8 and 9.
1H and 13C NMR Spectroscopic Data of Compounds 8 and 9.
| 8 (CD3OD) | 9 (CD3OD) | |||
|---|---|---|---|---|
| Position |
|
| ||
| 1 | 134.1 | 131.5 | ||
| 2 | 104.6c | 6.52 sd | 112.3 | 7.09 brs |
| 3 | 149.3 | 147.4 | ||
| 4 | 135.9 | 150.5 | ||
| 5 | 149.3 | 120.6 | 7.06 d (8.2) | |
| 6 | 104.6c | 6.52 sd | 121.1 | 6.96 dd (2.2, 8.2) |
| 7 | 85.1 | 4.63 d (7.3) | 74.9 | 4.85 overlap |
| 8 | 53.7 | 1.89 m | 85.9 | 4.36 m |
| 9 | 62.3 | 3.87 m | 62.2 | 3.82 m |
| 3.63 m | 3.47 m | |||
| 1′ | 139.5 | 137.8 | ||
| 2′ | 112.2 | 6.92 d (1.8) | 118.7g | 6.86 brsg |
| 3′ | 150.7 | 149.2 | ||
| 4′ | 147.5 | 118.7g | 6.86 brsg | |
| 5′ | 117.5 | 7.11 d (8.2) | 151.2 | |
| 6′ | 120.9 | 6.82 dd (8.2, 1.8) | 111.3 | 6.97 d (2.2) |
| 7′ | 74..8 | 4.52 d (8.2) | 132.9 | 6.52 d (15.4) |
| 8′ | 50.7 | 2.53 m | 111.3 | 6.27 dd (5.7, 15.4) |
| 9′ | 76.2 | 4.26 dd (9.0, 4.6) | 63.8 | 4.19 d (5.9) |
| 3.92 m | ||||
| 3-OMe | 56.9 | 3.84 se | 56.7 | 3.81 s |
| 5-OMe | 56.8 | 3.84 se | 56.5 | 3.79 s |
| 3′-OMe | 56.7 | 3.83 s | ||
| Glc-1 | 102.7 | 4.84 m | 103.1 | 4.81 d (6.9) |
| Glc-2 | 74.9 | 3.4–3.8 mf | 73.9 | 3.4–3.8 mh |
| Glc-3 | 78.2 | 3.4–3.8 mf | 78.2 | 3.4–3.8 mh |
| Glc-4 | 71.4 | 3.4–3.8 mf | 71.4 | 3.4–3.8 mh |
| Glc-5 | 77.9 | 3.4–3.8 mf | 77.9 | 3.4–3.8 mh |
| Glc-6 | 62.5 | 3.4–3.8 mf | 62.5 | 3.4–3.8 mh |
100 Hz, 400 Hz, – Overlapping signals.
Antiproliferative Activity of the Isolated Compounds.
| Compounds | Cell Lines | ||||
|---|---|---|---|---|---|
| A549 | MDA-MB-231 | MCF-7 | KB | KB-VIN | |
|
| >40 | 22.5 | >40 | 25.7 | 31.7 |
|
| 21.9 | 24.6 | 24.6 | 22.6 | 21.4 |
|
| 35.1 | 35.3 | 35.7 | 32.7 | 21.7 |
|
| 12.5 | 10.8 | 8.8 | 18.6 | 8.8 |
|
| 32.8 | 37.7 | 33.5 | >40 | 8.7 |
|
| 23.2 | 32.9 | 32.8 | 23.2 | 19.9 |
|
| 8.1 | 20.8 | 6.8 | 20.3 | 5.4 |
|
| 5.7 | 8.2 | 8.1 | 12.6 | 5.3 |
|
| 37.8 | >40 | 38.0 | >40 | 8.2 |
|
| >40 | >40 | >40 | >40 | >40 |
| Paclitaxel (nM) | 6.5 | 8.4 | 12.1 | 7.1 | 2213 |
A549 (lung carcinoma), MDA-MB-231 (triple-negative breast cancer), MCF-7 (estrogen receptor-positive & HER2-negative breast cancer), KB (cervical cancer cell line HeLa derivative), KB-VIN (P-gp-overexpressing multidrug-resistant (MDR) subline of KB). Antiproliferative activity expressed as IC50 values for each cell line cultured with compound for 72 h, the concentration of compound that caused 50% reduction relative to untreated cells determined by the SRB assay. IC50 of all compounds were calculated.